Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome

[This corrects the article on p. e281 in vol. 3, PMID: 27606356.].

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome

Neurobiology of Serotonin Norepinephrine Reuptake Inhibitors

Major depressive disorder (MDD) is a complex condition resulting from numerous genetic and physiologic factors. This article reviews the neurochemical mechanisms underlying MDD, summarizes recent genetic findings, and examines the efficacy of various treatments. The norepinephrine (NE) and serotonin (5-HT) pathways affect several areas of the nervous system that are disrupted in MDD, and agents...

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise

The precise mechanisms of pain perception and transmission in the central nervous system have not been fully elucidated. However, extensive data support a role for the monoamine neurotransmitters, serotonin and norepinephrine, in the modulation of pain. Experiments with animal models of pain indicate that noradrenergic interventions, and to a lesser extent serotonergic interventions, reduce pai...

Comparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors

Serotonin norepinephrine reuptake inhibitors (SNRIs) work by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine. This results in an increase in the extracellular concentrations of serotonin and norepinephrine and therefore an increase in neurotransmission. The three SNRIs milnacipran, duloxetine, and venlafaxine have different affinity and selectivity profiles. Milnac...